Literature DB >> 29567777

MK2 is a therapeutic target for high-risk multiple myeloma.

Chunyan Gu1, Haibo Cheng2, Hongbao Yang3, Yong Bian4, Yaohui Wang5, Yifen Zhang5, Michael Pisano1, Gang Hu6, Ye Yang7.   

Abstract

Entities:  

Year:  2021        PMID： 29567777     DOI： 10.3324/haematol.2017.182121

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

Review 1.  Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.

Authors:  Dauren Alimbetov; Sholpan Askarova; Bauyrzhan Umbayev; Terence Davis; David Kipling
Journal:  Int J Mol Sci       Date:  2018-06-06       Impact factor: 5.923

2.  Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma.

Authors:  Mengjie Guo; Dongdong Sun; Zhimin Fan; Yuxia Yuan; Miaomiao Shao; Jianhao Hou; Yuqi Zhu; Rongfang Wei; Yan Zhu; Jinjun Qian; Fei Li; Ye Yang; Chunyan Gu
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

3.  DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma.

Authors:  Jean-Baptiste Alberge; Florence Magrangeas; Mirko Wagner; Soline Denié; Catherine Guérin-Charbonnel; Loïc Campion; Michel Attal; Hervé Avet-Loiseau; Thomas Carell; Philippe Moreau; Stéphane Minvielle; Aurélien A Sérandour
Journal:  Clin Epigenetics       Date:  2020-11-02       Impact factor: 6.551

4.  AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.

Authors:  Chunyan Gu; Yajun Wang; Lulin Zhang; Li Qiao; Shanliang Sun; Miaomiao Shao; Xiaozhu Tang; Pinggang Ding; Chao Tang; Yuhao Cao; Yanyan Zhou; Mengjie Guo; Rongfang Wei; Nianguang Li; Yibei Xiao; Jinao Duan; Ye Yang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06

5.  CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.

Authors:  Chunyan Gu; Wang Wang; Xiaozhu Tang; Tingting Xu; Yanxin Zhang; Mengjie Guo; Rongfang Wei; Yajun Wang; Artur Jurczyszyn; Siegfried Janz; Meral Beksac; Fenghuang Zhan; Anja Seckinger; Dirk Hose; Jingxuan Pan; Ye Yang
Journal:  Mol Cancer       Date:  2021-06-05       Impact factor: 27.401
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.